Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PARP inhibition and immunotherapy: a promising duo in fighting cancer.
Phillipps J, Zhou AY, Butt OH, Ansstas G. Phillipps J, et al. Among authors: ansstas g. Transl Cancer Res. 2023 Sep 30;12(9):2433-2437. doi: 10.21037/tcr-23-726. Epub 2023 Aug 3. Transl Cancer Res. 2023. PMID: 37859734 Free PMC article. No abstract available.
Homologous Recombination Deficiency (HRD) in Cutaneous Oncology.
Akinjiyan FA, Morecroft R, Phillipps J, Adeyelu T, Elliott A, Park SJ, Butt OH, Zhou AY, Ansstas G. Akinjiyan FA, et al. Among authors: ansstas g. Int J Mol Sci. 2023 Jun 28;24(13):10771. doi: 10.3390/ijms241310771. Int J Mol Sci. 2023. PMID: 37445949 Free PMC article. Review.
A phase II study of laser interstitial thermal therapy combined with doxorubicin in patients with recurrent glioblastoma.
Butt OH, Zhou AY, Huang J, Leidig WA, Silberstein AE, Chheda MG, Johanns TM, Ansstas G, Liu J, Talcott G, Nakiwala R, Shimony JS, Kim AH, Leuthardt EC, Tran DD, Campian JL. Butt OH, et al. Among authors: ansstas g. Neurooncol Adv. 2021 Nov 15;3(1):vdab164. doi: 10.1093/noajnl/vdab164. eCollection 2021 Jan-Dec. Neurooncol Adv. 2021. PMID: 34988450 Free PMC article.
Corrigendum to: A phase II study of laser interstitial thermal therapy combined with doxorubicin in patients with recurrent glioblastoma.
Butt OH, Zhou AY, Huang J, Leidig WA, Silberstein AE, Chheda MG, Johanns TM, Ansstas G, Liu J, Talcott G, Nakiwala R, Shimony JS, Kim AH, Leuthardt EC, Tran DD, Campian JL. Butt OH, et al. Among authors: ansstas g. Neurooncol Adv. 2022 Apr 29;4(1):vdac042. doi: 10.1093/noajnl/vdac042. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 35505674 Free PMC article.
A randomized feasibility study evaluating temozolomide circadian medicine in patients with glioma.
Damato AR, Katumba RGN, Luo J, Atluri H, Talcott GR, Govindan A, Slat EA, Weilbaecher KN, Tao Y, Huang J, Butt OH, Ansstas G, Johanns TM, Chheda MG, Herzog ED, Rubin JB, Campian JL. Damato AR, et al. Among authors: ansstas g. Neurooncol Pract. 2022 Jan 31;9(3):193-200. doi: 10.1093/nop/npac003. eCollection 2022 May. Neurooncol Pract. 2022. PMID: 35601970 Free PMC article.
55 results